Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F. Wang(Sun Yat-sen University), Rui‐Hua Xu(Sun Yat-sen University), Xiandong Lin(Fujian Medical University), Qilong Zhang(Harbin Medical University), Yanshi Liu(First Hospital of China Medical University), Quan Li(Shanghai Jiao Tong University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), J.W. Wang(Sun Yat-sen University), Yi Jiang(Nanjing University of Chinese Medicine), Fenggong Wang(Sun Yat-sen University), Sheng Yao(BioReliance (United States)), Yongqian Shu(Jiangsu Province Hospital), Y. Chen(Sichuan University), Lin Shen(Hangzhou Normal University), Xiang Hu(Wenzhou Medical University), Guanghai Dai(Chinese PLA General Hospital), Xianglin Yuan(Tongji Hospital), Xiaoli Wei(Anhui Medical University), J. Feng(Hangzhou First People's Hospital), Nong Xu(Zhejiang University), H. T. Wu, Jiawei Shi(Union Hospital), W. Li(Jilin University), S. Yang(Zhengzhou University), Hui Feng(Boston University)
Cited by 475
Related Papers
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
|Molecular Cancer|2020|1k
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
|Advanced Materials|2017|756